Q2 2021 Results - Reimagining Medicine
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis pipeline in Phase 1 (2 of 2)
Immunology, Hepatology, Dermatology
Mechanism
Code
Name
CEE321 CEE321
DFV890 DFV890
FIA586 FIA586
MHS552 MHS552
MHV370 MHV370
NG1226 NG1226
Neuroscience
Name
Code
OAV201
OAV201 (AVXS-201)
NIO752
NIO752
LMI070
branaplam
Pan JAK inhibitor
Indication(s)
Atopic dermatitis
Anti-inflammatory therapy
Non-alcoholic steatohepatitis (NASH)
Autoimmune indications
Sjögren's
Tendinopathy
Systemic lupus erythematosus
Mechanism
Indication(s)
MECP2 gene therapy
Rett syndrome
Tau antagonist
Neurodegenerative diseases
mRNA splicing modulator
Huntington's disease
Ophthalmology
Code
MHU650
Name
Mechanism
MHU650
49 Investor Relations | Q2 2021 Results
Respiratory Disease
Code
Name
LTP001 LTP001
NCJ424 NCJ424
Mechanism
References
Innovation: Clinical trials
38 lead indications
Lead indication
Indication(s)
Respiratory diseases
Respiratory diseases
Cardiovascular, Renal, Metabolism
Code
Name
MBL949 MBL949
Mechanism
Indication(s)
Obesity related diseases
Global Health
Indication(s)
Code
KAF156
Diabetic eye diseases
INE963
Name
ganaplacide
INE963
Mechanism
Indication(s)
Malaria prophylaxis
Malaria, uncomplicated
NOVARTIS | Reimagining MedicineView entire presentation